AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
Alnylam Pharmaceuticals Inc ALNY
News
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
(NASDAQ: ALNY) Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. Investors to Contact the Firm
ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis
Here's the somewhat surprising stock that will soon join the S&P 500
Walmart was too late for a Nasdaq-100 spot - but these 6 stocks made the cut
Roche, Alnylam Move Hypertension Drug to Late-Stage Trial
United States